TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 213 filers reported holding TURNING POINT THERAPEUTICS I in Q2 2022. The put-call ratio across all filers is 3.08 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $27,576,000 | +6916.8% | 366,453 | +2403.3% | 0.03% | – |
| Q1 2022 | $393,000 | -86.6% | 14,639 | -76.1% | 0.00% | -100.0% |
| Q4 2021 | $2,928,000 | -70.4% | 61,254 | -58.9% | 0.00% | -75.0% |
| Q3 2021 | $9,900,000 | +40.7% | 149,028 | +65.2% | 0.01% | +33.3% |
| Q2 2021 | $7,038,000 | +30.9% | 90,214 | +58.7% | 0.01% | +20.0% |
| Q1 2021 | $5,377,000 | -34.0% | 56,841 | -15.0% | 0.01% | -37.5% |
| Q4 2020 | $8,144,000 | +52.0% | 66,842 | +9.0% | 0.01% | +33.3% |
| Q3 2020 | $5,357,000 | +46.3% | 61,329 | +8.2% | 0.01% | +50.0% |
| Q2 2020 | $3,661,000 | +17.8% | 56,680 | -18.6% | 0.00% | 0.0% |
| Q1 2020 | $3,109,000 | +11.6% | 69,610 | +55.6% | 0.00% | +33.3% |
| Q4 2019 | $2,786,000 | +23.0% | 44,727 | -25.9% | 0.00% | +50.0% |
| Q3 2019 | $2,265,000 | +326.6% | 60,348 | +362.2% | 0.00% | – |
| Q2 2019 | $531,000 | – | 13,058 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 708,233 | $44,116,000 | 18.91% |
| Corriente Advisors, LLC | 285,000 | $17,753,000 | 9.54% |
| Cormorant Asset Management, LP | 3,396,650 | $211,577,000 | 8.44% |
| Opaleye Management Inc. | 340,500 | $21,210,000 | 4.16% |
| Orbimed Advisors | 2,745,327 | $171,006,000 | 2.44% |
| Parkman Healthcare Partners LLC | 101,434 | $6,318,000 | 1.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,000 | $2,179,000 | 0.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 366,000 | $22,798,000 | 0.73% |
| Artal Group S.A. | 300,000 | $18,687,000 | 0.72% |
| DAFNA Capital Management LLC | 30,408 | $1,894,000 | 0.65% |